Meridian Medicaid Drug List Changes starting 11/1/2026

Humira (brand name) autoinjector and prefilled syringe
[adalimumab]
(10mg/0.1mL, 20mg/0.2mL, 40mg/0.4mL, 40mg/0.8mL, 80mg/0.8mL)

• Moved from preferred to non-preferred
• Prior Authorization Required
• Remains with Quantity Limits (variable by drug strength & formulation, refer to formulary search tool for product-specific limits)
• Quantity Limit Note: induction/loading doses can be approved for over Quantity Limit

Hadlima autoinjector and prefilled syringe
[adalimumab-bwwd]
(40mg/0.4mL, 40mg/0.8mL)

• Moved from non-preferred to preferred
• Removed Prior Authorization requirement
• Remains with Quantity Limits (4 devices per 28 days)
• Quantity Limit Note: induction/loading doses can be approved for over Quantity Limit

Cosentyx Sensoready Pen, Unoready Pen, and prefilled syringe
[secukinumab]
(150mg/1mL, 300mg/2mL, 75mg/0.5mL)

• Moved from preferred to non-preferred
• Prior Authorization Required
• Remains with Quantity Limits (variable by drug strength & formulation, refer to formulary search tool for product-specific limits)
• Quantity Limit Note: induction/loading doses can be approved for over Quantity Limit
• **Grandfathering of existing utilizers is being applied for 1 year -- only for patients using Cosentyx to treat a diagnosis of hidradenitis suppurativa**

Taltz autoinjector and prefilled syringe
[ixekizumab]
(20mg/0.25mL, 40mg/0.5mL, 80mg/1mL)

• Moved from non-preferred to preferred
• Remains with Prior Authorization required
• Remains with Quantity Limits (1 device per 28 days)
• Quantity Limit Note: induction/loading doses can be approved for over Quantity Limit

Starjemza prefilled syringe, vial for subcutaneous injection, vial for intravenous infusion
[ustekinumab-hmny]
(45mg/0.4mL, 90mg/1mL, 130mg/26mL)

• Moved from non-preferred to preferred
• Remains Prior Authorization required
• Remains with Quantity Limits (variable by drug strength & formulation, refer to formulary search tool for product-specific limits)
• Quantity Limit Note: induction/loading doses can be approved for over Quantity Limit

Steqeyma prefilled syringe, vial for subcutaneous injection, vial for intravenous infusion
[ustekinumab-stba]
(45mg/0.4mL, 90mg/1mL, 130mg/26mL)

• Moved from preferred to non-preferred
• Remains Prior Authorization required
• Remains with Quantity Limits (variable by drug strength & formulation, refer to formulary search tool for product-specific limits)
• Quantity Limit Note: induction/loading doses can be approved for over Quantity Limit

Tyenne autoinjector & prefilled syringe
[tocilizumab-aazg]
(162mg/0.9mL)

• Moved from non-preferred to preferred
• Remains Prior Authorization required
• Remains with Quantity Limit : 4 devices per 28 days

Avtozma autoinjector & prefilled syringe
[tocilizumab-anoh]
(162mg/0.9mL)

• Added to formulary as non-preferred
• Prior Authorization required
• Quantity Limit : 4 devices per 28 days

Icotyde oral tablet
[icotrokinra]
(200mg)

• Added to formulary as non-preferred
• Prior Authorization required
• Quantity Limit : 30 tablets per 30 days
• Age Limit: minimum age 12 years old

Janumet XR oral extended-release tablet (brand name)
[sitagliptin-metformin]
(50-500mg, 50-1000mg, 100-1000mg)

• Moved from preferred to non-preferred
• Prior Authorization Required
• Note: generic version remains non-preferred
• **Grandfathering of existing utiliz